Fig. 2From: PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaTreatment schedule. Frequency and dosing of nivolumab and ipilimumab for both arms of the study are shownBack to article page